Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Pirtobrutinib in Relapsed or Refractory B-Cell Malignancies (BRUIN): A Phase 1/2 Study
Lancet 2021 Mar 06;397(10277)892-901, AR Mato, NN Shah, W Jurczak, CY Cheah, JM Pagel, JA Woyach, B Fakhri, TA Eyre, N Lamanna, MR Patel, A Alencar, E Lech-Maranda, WG Wierda, CC Coombs, JN Gerson, P Ghia, S Le Gouill, DJ Lewis, S Sundaram, JB Cohen, IW Flinn, CS Tam, MA Barve, B Kuss, J Taylor, O Abdel-Wahab, SJ Schuster, ML Palomba, KL Lewis, LE Roeker, MS Davids, XN Tan, TS Fenske, J Wallin, DE Tsai, NC Ku, E Zhu, J Chen, M Yin, B Nair, K Ebata, N Marella, JR Brown, M WangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.